MarketResearch.com has announced the addition of the new report "The Ophthalmic Pharmaceutical Market Outlook to 2016" to their collection of Therapeutic Area market reports
The $16.2 billion ophthalmic pharmaceutical market will grow steadily at a CAGR of 4.6% to 2016. Although glaucoma is the largest segment most of the growth will come from retinal diseases such as age-related macular degeneration and diabetic retinopathy.
Glaucoma is the largest segment within the ophthalmic market, with sales of $5.6bn in 2010, which will grow at a CAGR of 2.5% to 2016. Xalatan sales are eroding in the US since its patent expiry in March 2011. If an EU pediatric extension is granted the brand will remain protected until January 2012.
Increased use of contact lenses and computers has led to increase dry eye syndrome (DES) in younger age groups. Despite this artificial tear market is expected to be static to 2016.
The retinal disease segment which includes age-related macular degeneration (AMD), diabetic retinopathy (DR), diabetic macular edema (DME) and retinal vein occlusion (RVO) was valued at $3.5bn in 2010, and will be the fastest growing area with a CAGR of 14.1% to 2016.
No comments:
Post a Comment